The National Cancer Research Center of Japan and Cihui University of Japan have discovered a new treatment for cancer patients with ARID1A mutations. The ARID1A gene produces proteins that act as SWI/SNF chromatin remodeling complexes that promote expression of various genes. Mutations in the ARID1A gene can cause cancer-specific cancers such as ovarian clear cell carcinoma, endometrial cancer, and ovarian endometrioid carcinoma. ARID1A protein defects are also present in cancers commonly found in Asians such as gastric cancer and biliary tract cancer. These cancers deteriorate as the disease progresses, so there is an urgent need to develop effective therapeutic drugs.
The R&D team found that a loss-of-function mutation, a major feature of the ARID1A gene mutation, caused metabolic abnormalities and successfully found a treatment by inhibiting this metabolic abnormality. This method of treating cancer with a loss-of-function mutation is called "synthetic lethal therapy" and is used as a new treatment method for the treatment of breast cancer and ovarian cancer with BRCA1 and BRCA2 gene mutations. (Source of this column: Japan Science and Technology Promotion Agency: Chen Chao, a reporter in Japan)
Source: Technology Daily
Vital Signs Monitor,Pulse Oximeter,Oxygen Concentrator,Patient Monitor,valve inflatable extension tube
Anesthesia Medical Co., Ltd. , https://www.jssinoanesthesias.com